IFN alpha 2a Protein
Conditions of optimal IFN alpha 2a Protein performance should be determined experimentally by the investigator.
ALTIRATINIB (DCC-2701)
Background Information: Abstract (Ref 1): Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer. Specifically, Altiratinib inhibits not only mechanisms of tumor initiation and...